These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 38977966)

  • 1. Selective anti-tumor activity of glutathione-responsive abasic site trapping agent in anaplastic thyroid carcinoma.
    Chai J; Su M; Zhang R; Li N; Jia Y; Zheng W; Tan J; Jia Q; Sun H; Meng Z
    BMC Cancer; 2024 Jul; 24(1):816. PubMed ID: 38977966
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Selective Antitumor Activity and Photocytotoxicity of Glutathione-Activated Abasic Site Trapping Agents.
    Xue L; Yu D; Wang L; Sun J; Song Y; Jia Y; Wu A; Zhang B; Mi W; Fan H; Sun H
    ACS Chem Biol; 2022 Apr; 17(4):797-803. PubMed ID: 35297620
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ym155 Induces Oxidative Stress-Mediated DNA Damage and Cell Cycle Arrest, and Causes Programmed Cell Death in Anaplastic Thyroid Cancer Cells.
    Xu Q; Mackay RP; Xiao AY; Copland JA; Weinberger PM
    Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33669447
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Disrupting glycolysis and DNA repair in anaplastic thyroid cancer with nucleus-targeting platinum nanoclusters.
    Pan Z; Lu X; Hu X; Yu R; Che Y; Wang J; Xiao L; Chen J; Yi X; Tan Z; Li F; Ling D; Huang P; Ge M
    J Control Release; 2024 May; 369():517-530. PubMed ID: 38569942
    [TBL] [Abstract][Full Text] [Related]  

  • 5. KLF5 influences cell biological function and chemotherapy sensitivity through the JNK signaling pathway in anaplastic thyroid carcinoma.
    Wang Z; Qiu X; Zhang H; Li W
    J Biochem Mol Toxicol; 2020 May; 34(5):e22469. PubMed ID: 32173973
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Torin2 targets dysregulated pathways in anaplastic thyroid cancer and inhibits tumor growth and metastasis.
    Sadowski SM; Boufraqech M; Zhang L; Mehta A; Kapur P; Zhang Y; Li Z; Shen M; Kebebew E
    Oncotarget; 2015 Jul; 6(20):18038-49. PubMed ID: 25945839
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Signal transducer and activator of transcription 3 inhibition alleviates resistance to BRAF inhibition in anaplastic thyroid cancer.
    Wang Y; Hu Z; Ma W; Niu Y; Su J; Zhang L; Zhao P
    Invest New Drugs; 2021 Jun; 39(3):764-774. PubMed ID: 33245464
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potentiated anti-tumor effects of BETi by MEKi in anaplastic thyroid cancer.
    Zhu X; Park S; Lee WK; Cheng SY
    Endocr Relat Cancer; 2019 Sep; 26(9):739-750. PubMed ID: 31272080
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The EPRS-ATF4-COLI pathway axis is a potential target for anaplastic thyroid carcinoma therapy.
    Mi L; Liu J; Zhang Y; Su A; Tang M; Xing Z; He T; Wei T; Li Z; Wu W
    Phytomedicine; 2024 Jul; 129():155670. PubMed ID: 38704915
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of Krüppel-Like Factor 4 in the Maintenance of Chemoresistance of Anaplastic Thyroid Cancer.
    Lee SI; Kim DK; Seo EJ; Choi EJ; Kwon YW; Jang IH; Lee JC; Kim HY; Shong M; Kim JH; Kim SJ
    Thyroid; 2017 Nov; 27(11):1424-1432. PubMed ID: 28920531
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alantolactone induces concurrent apoptosis and GSDME-dependent pyroptosis of anaplastic thyroid cancer through ROS mitochondria-dependent caspase pathway.
    Hu Y; Wen Q; Cai Y; Liu Y; Ma W; Li Q; Song F; Guo Y; Zhu L; Ge J; Zeng Q; Wang J; Yin C; Zheng G; Ge M
    Phytomedicine; 2023 Jan; 108():154528. PubMed ID: 36343549
    [TBL] [Abstract][Full Text] [Related]  

  • 12. miR-148a inhibits self-renewal of thyroid cancer stem cells via repressing INO80 expression.
    Sheng W; Chen Y; Gong Y; Dong T; Zhang B; Gao W
    Oncol Rep; 2016 Dec; 36(6):3387-3396. PubMed ID: 27779717
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reduced apurinic/apyrimidinic endonuclease activity enhances the antitumor activity of oxymatrine in lung cancer cells.
    Wang Z; Xu W; Lin Z; Li C; Wang Y; Yang L; Liu G
    Int J Oncol; 2016 Dec; 49(6):2331-2340. PubMed ID: 27748797
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synergy between isobavachalcone and doxorubicin suppressed the progression of anaplastic thyroid cancer through ferroptosis activation.
    Lin S; Cai H; Song X
    Braz J Med Biol Res; 2024; 57():e13679. PubMed ID: 39166605
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lenvatinib exhibits antineoplastic activity in anaplastic thyroid cancer in vitro and in vivo.
    Ferrari SM; Bocci G; Di Desidero T; Elia G; Ruffilli I; Ragusa F; Orlandi P; Paparo SR; Patrizio A; Piaggi S; La Motta C; Ulisse S; Baldini E; Materazzi G; Miccoli P; Antonelli A; Fallahi P
    Oncol Rep; 2018 May; 39(5):2225-2234. PubMed ID: 29517103
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of the human apurinic/apyrimidinic endonuclease (APE1) repair activity and sensitization of breast cancer cells to DNA alkylating agents with lucanthone.
    Luo M; Kelley MR
    Anticancer Res; 2004; 24(4):2127-34. PubMed ID: 15330152
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of mesoporous silica nanoparticles co‑loading with 17‑AAG and Torin2 on anaplastic thyroid carcinoma by targeting VEGFR2.
    Wang C; Zhang R; Tan J; Meng Z; Zhang Y; Li N; Wang H; Chang J; Wang R
    Oncol Rep; 2020 May; 43(5):1491-1502. PubMed ID: 32323855
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sorafenib and Quinacrine Target Anti-Apoptotic Protein MCL1: A Poor Prognostic Marker in Anaplastic Thyroid Cancer (ATC).
    Abdulghani J; Gokare P; Gallant JN; Dicker D; Whitcomb T; Cooper T; Liao J; Derr J; Liu J; Goldenberg D; Finnberg NK; El-Deiry WS
    Clin Cancer Res; 2016 Dec; 22(24):6192-6203. PubMed ID: 27307592
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Carfilzomib is an effective anticancer agent in anaplastic thyroid cancer.
    Mehta A; Zhang L; Boufraqech M; Zhang Y; Patel D; Shen M; Kebebew E
    Endocr Relat Cancer; 2015 Jun; 22(3):319-29. PubMed ID: 25972243
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A dominant-negative form of the major human abasic endonuclease enhances cellular sensitivity to laboratory and clinical DNA-damaging agents.
    McNeill DR; Wilson DM
    Mol Cancer Res; 2007 Jan; 5(1):61-70. PubMed ID: 17259346
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.